Aberdeen Group’s CARGO Therapeutics CRGX Stock Holding History

Aberdeen Group’s Portfolio CRGX Stock Details CRGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-41,124	Closed	-$593K	–	947
2024 Q4	$593K	Buy	+41,124	New	+$746K	﹤0.01%	863

Other funds holding CRGX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TGV

TRV GP VI Boston, Massachusetts $136M AUM 328.39% 1-Year Est. Return

Aberdeen Group's CRGX Position: Q1 2025 in Review

Aberdeen Group sold out of CARGO Therapeutics (CRGX) in Q1 2025, closing a stake of 41,124 shares — an estimated $593K sold.

Aberdeen Group first reported a position in CRGX in Q4 2024 and held it in 1 quarter. The position peaked at $593K in Q4 2024. 113 funds tracked by Wall St. Rank hold CRGX as of Q1 2025.

Aberdeen Group reported no remaining CARGO Therapeutics position as of Q1 2025 after selling out during the quarter.
Aberdeen Group sold 41,124 CARGO Therapeutics shares in Q1 2025, an estimated $593K.
Aberdeen Group first reported a position in CARGO Therapeutics in Q4 2024 and held it in 1 quarter.
Aberdeen Group's CARGO Therapeutics position peaked at $593K in Q4 2024.
113 funds tracked by Wall St. Rank held CARGO Therapeutics as of Q1 2025.

Based on Aberdeen Group's 13F filing for Q1 2025, filed 13 May 2025.